Nature

Figures and Tables

From the following article:

Dynamics of chronic myeloid leukaemia

Franziska Michor, Timothy P. Hughes, Yoh Iwasa, Susan Branford, Neil P. Shah, Charles L. Sawyers and Martin A. Nowak

Nature 435, 1267-1270 (30 June 2005)

doi: 10.1038/nature03669

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 1

Imatinib leads to a biphasic decline of leukaemic cells.

Full size figure and legend (75K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 2

Discontinuation of imatinib therapy in three patients after 1−3 years led to a rapid increase of leukaemic cells to levels at or beyond pre-treatment baseline.

Full size figure and legend (57K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 3

About 40 different point mutations in BCR-ABL have been identified that confer various degrees of resistance to imatinib therapy.

Full size figure and legend (55K)
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 4

Model dynamics of different treatment responses to imatinib.

Full size figure and legend (78K)
BACK TO ARTICLE